This Article Full Text (PDF) All Versions of this Article: 1352458506070732v1 13/2/256    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (23) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Papeix, C Articles by Gout, O Search for Related Content PubMed PubMed Citation Articles by Papeix, C Articles by Gout, O Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France, caroline.papeix{at}psl.ap-hop-paris.fr

J-S Vidal

Institut National de la Santé et de la Recherche Médicale Unité 708, Hôpital de la Salpêtrie`re, Paris, France

J de Seze

Department of Neurology, CHU de Lille, Lille, France

C Pierrot-Deseilligny

Department of Neurology, Hôpital de la Salpêtrière, Paris, France

A Tourbah

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France, Department of Internal Medicine, CHNO XV/XX, Paris, France

B Stankoff

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France, Centre d’Investigation Clinique, Hôpital de la Salpêtrie`re, Paris, France

C Lebrun

Department of Neurology, CHU de Nice, Nice, France

T Moreau

Department of Neurology, CHU de Dijon, Dijon, France

P Vermersch

Department of Neurology, CHU de Lille, Lille, France

B Fontaine

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France

O Lyon-Caen

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France

O Gout

Department of Neurology, Fondation Ophtalmologique A. de Rothschild, Paris, France

To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P =0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants.

Key Words: beta interferon • immunosuppressive therapy • neuromyelitis optica

This version was published on March 1, 2007

Multiple Sclerosis, Vol. 13, No. 2, 256-259 (2007)
DOI: 10.1177/1352458506070732


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P Cabre, A Gonzalez-Quevedo, M Bonnan, A Saiz, S Olindo, F Graus, D Smadja, H Merle, L Thomas, and J A Cabrera-Gomez Relapsing neuromyelitis optica: long term history and clinical predictors of death J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1162 - 1164. [Abstract] [Full Text] [PDF]

				M Bonnan, R Valentino, S Olindo, H Mehdaoui, D Smadja, and P Cabre Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder Multiple Sclerosis, April 1, 2009; 15(4): 487 - 492. [Abstract] [PDF]

				D. Miller, B. Weinshenker, M Filippi, B. Banwell, J. Cohen, M. Freedman, S. Galetta, M Hutchinson, R. Johnson, L Kappos, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach Multiple Sclerosis, November 1, 2008; 14(9): 1157 - 1174. [Abstract] [PDF]

				A. Jacob, B. G. Weinshenker, I. Violich, N. McLinskey, L. Krupp, R. J. Fox, D. M. Wingerchuk, M. Boggild, C. S. Constantinescu, A. Miller, et al. Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients Arch Neurol, November 1, 2008; 65(11): 1443 - 1448. [Abstract] [Full Text] [PDF]

				S Jarius, D Franciotta, R Bergamaschi, S Rauer, K P Wandinger, H F Petereit, M Maurer, H Tumani, A Vincent, P Eichhorn, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1134 - 1136. [Abstract] [Full Text] [PDF]

				P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al. Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis Arch Neurol, July 1, 2008; 65(7): 913 - 919. [Abstract] [Full Text] [PDF]

				J. de Seze, F. Blanc, L. Jeanjean, H. Zephir, P. Labauge, M. Bouyon, L. Ballonzoli, G. Castelnovo, M. Fleury, S. Defoort, et al. Optical Coherence Tomography in Neuromyelitis Optica Arch Neurol, July 1, 2008; 65(7): 920 - 923. [Abstract] [Full Text] [PDF]

				M. Matiello, V. A. Lennon, A. Jacob, S. J. Pittock, C. F. Lucchinetti, D. M. Wingerchuk, and B. G. Weinshenker NMO-IgG predicts the outcome of recurrent optic neuritis Neurology, June 3, 2008; 70(23): 2197 - 2200. [Abstract] [Full Text] [PDF]

				J. de Seze, C. Arndt, L. Jeanjean, H. Zephir, F. Blanc, P. Labauge, M. Bouyon, L. Ballonzoli, M. Fleury, P. Vermersch, et al. RELAPSING INFLAMMATORY OPTICNEURITIS: IS IT NEUROMYELITIS OPTICA? Neurology, May 27, 2008; 70(22): 2075 - 2076. [Full Text] [PDF]